Evidence map›Paper›PMID 19196468›Full record

Trial reportSubstance abuse treatment, prevention, and policy2009

The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project: a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification.

Laura Sheard, Nat M J Wright, Hany G El-Sayeh, Clive E Adams, Ryan Li, Charlotte N E Tompkins

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Substance abuse treatment, prevention, and policy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 9 pooled it
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 9 syntheses or guidelines pooled it, 92 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Interventions for female drug-using offenders.The Cochrane database of systematic reviews · 2019
    Pooled it
  5. Pooled it
  6. Buprenorphine for managing opioid withdrawal.The Cochrane database of systematic reviews · 2017
    Pooled it
  7. Pharmacological interventions for drug-using offenders.The Cochrane database of systematic reviews · 2015
    Pooled it
  8. Pooled it
  9. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial.The British journal of general practice : the journal of the Royal College of General Practitioners · 2011
    Pooled it
  10. Trial
  11. Trial
  12. Review
  13. Review
  14. Newer approaches to opioid detoxification.Industrial psychiatry journal · 2012
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Laura SheardLeeds Institute of Health Sciences, Charles Thackrah Building, 101 Clarendon Road, Leeds, LS2 9LJ, UK. l.sheard@leeds.ac.uk
Nat M J Wright
Hany G El-Sayeh
Clive E Adams
Ryan Li
Charlotte N E Tompkins
University of Leeds · GBHarrogate District Hospital · GBLeeds Dental Hospital · GBUniversity College London · GBUniversity of Nottingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany opiate users entering British prisons require prescribed medication to help them achieve abstinence. This commonly takes the form of a detoxification regime. Previously, a range of detoxification agents have been prescribed without a clear evidence base to recommend a drug of choice. There are few trials and very few in the prison setting. This study compares dihydrocodeine with buprenorphine.

methodsOpen label, pragmatic, randomised controlled trial in a large remand prison in the North of England. Ninety adult male prisoners requesting an opiate detoxification were randomised to receive either daily sublingual buprenorphine or daily oral dihydrocodeine, given in the context of routine care. All participants gave written, informed consent. Reducing regimens were within a standard regimen of not more than 20 days and were at the discretion of the prescribing doctor. Primary outcome was abstinence from illicit opiates as indicated by a urine test at five days post detoxification. Secondary outcomes were collected during the detoxification period and then at one, three and six months post detoxification. Analysis was undertaken using relative risk tests for categorical data and unpaired t-tests for continuous data.

results64% of those approached took part in the study. 63 men (70%) gave a urine sample at five days post detoxification. At the completion of detoxification, by intention to treat analysis, a higher proportion of people allocated to buprenorphine provided a urine sample negative for opiates (abstinent) compared with those who received dihydrocodeine (57% vs 35%, RR 1.61 CI 1.02-2.56). At the 1, 3 and 6 month follow-up points, there were no significant differences for urine samples negative for opiates between the two groups. Follow up rates were low for those participants who had subsequently been released into the community.

conclusionThese findings would suggest that dihydrocodeine should not be routinely used for detoxification from opiates in the prison setting. The high relapse rate amongst those achieving abstinence would suggest the need for an increased emphasis upon opiate maintenance programmes in the prison setting.

trial registrationCurrent Controlled Trials ISRCTN07752728.

Indexed as

AdultAnalgesics, OpioidBuprenorphineCodeineEnglandFollow-Up StudiesHumansInactivation, MetabolicMaleMiddle AgedOpioid-Related DisordersPrisonersPrisonsSubstance Abuse DetectionTreatment OutcomeYoung AdultAnalgesics, OpioidBuprenorphineCodeinedihydrocodeine

Identifiers

PMID19196468
PMCPMC2649065
OpenAlexW2166655500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.